US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvectis Pharma, Inc.

8.99

-0.2300-2.49%

Post-market: 8.990.00000.00%18:57 EDT

Volume:124.08K

Turnover:1.12M

Market Cap:210.29M

PE:-7.97

High:9.43

Open:9.19

Low:8.81

Close:9.22

Loading ...

Overview Company News Filings

Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying

Simply Wall St.

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Nuvectis Pharma reports data from Phase 1b study of NXP800

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating

Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study

US Stocks Edge Lower; Cisco Earnings Top Views

Nuvectis Pharma Inc trading resumes

Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage

MT Newswires Live

Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast

MT Newswires Live

BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer

Nuvectis Pharma Inc - Additional Phase 1B Clinical Data Expected in Q2 2025

THOMSON REUTERS

Nuvectis Pharma Reports Encouraging Nxp800 Interim Data Supporting Ongoing Enrollment in Phase 1B Study in Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer

THOMSON REUTERS

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVCT/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVCT\",,,,,undefined,":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":8.99,"timestamp":1746820800000,"preClose":9.22,"halted":0,"volume":124081,"hourTrading":{"tag":"盘后","latestPrice":8.99,"preClose":8.99,"latestTime":"18:57 EDT","volume":3364,"amount":30256.276,"timestamp":1746831439843},"delay":0,"floatShares":12768280,"shares":23391499,"eps":-1.127275,"marketStatus":"Market Closed","change":-0.23,"latestTime":"05-09 16:00:00 EDT","open":9.19,"high":9.43,"low":8.805,"amount":1115728.783059,"amplitude":0.067787,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.127275,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":9.22,"postHourTrading":{"tag":"盘后","latestPrice":8.99,"preClose":8.99,"latestTime":"18:57 EDT","volume":3364,"amount":30256.276,"timestamp":1746831439843},"volumeRatio":0.8554067739304279,"impliedVol":1.0689,"impliedVolPercentile":0.2474},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVCT\",,,,,undefined,":{"symbol":"NVCT","floatShares":12768280,"roa":"-52.69%","roe":"-115.28%","lyrEps":-1.110256,"volumeRatio":0.8554067739304279,"shares":23391499,"dividePrice":0,"high":9.43,"amplitude":0.067787,"preClose":9.22,"low":8.805,"week52Low":4.44,"pbRate":"10.04","week52High":11.8,"institutionHeld":0,"latestPrice":8.99,"eps":-1.127275,"divideRate":0,"volume":124081,"delay":0,"ttmEps":-1.127275,"open":9.19,"prevYearClose":5.41,"prevWeekClose":9.25,"prevMonthClose":9.96,"prevQuarterClose":9.77,"fiveDayClose":9.25,"twentyDayClose":8.525,"sixtyDayClose":6.86},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVCT\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2495561925","title":"Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2495561925","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495561925?lang=en_us&edition=fundamental","pubTime":"2024-12-29 20:58","pubTimestamp":1735477124,"startTime":"0","endTime":"0","summary":"Key Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth 57% of the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/news/great-week-for-nuvectis-pharma-inc-nasdaqnvct-insiders-who-h-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","IE00B64PRP62.GBP","SQQQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","QID","NVCT","BK4588","NVIW.SI","NQmain","BK4112","USAW.SI","BK4139","QLD",".IXIC","NDAQ","TSYW.SI","LU2210150020.SGD","LU2095319765.USD","MNQmain","LU2210149790.SGD","USJW.SI","PSQ","IE00BGHQF748.EUR","TQQQ"],"gpt_icon":1},{"id":"2490018386","title":"Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2490018386","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490018386?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"Company ContactRon BentsurChairman, Chief Executive Officer and President201-614-3151rbentsur@nuvectis.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fFNAnlsaHnYf4MSp6iq2IA--~B/aD0zNTA7dz02ODk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bfb8e771b116075add0efd2a67d56cac","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fFNAnlsaHnYf4MSp6iq2IA--~B/aD0zNTA7dz02ODk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/bfb8e771b116075add0efd2a67d56cac"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-present-2024-ladenburg-130000478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4211","NVCT","ISBC"],"gpt_icon":0},{"id":"2486321820","title":"Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486321820","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486321820?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:55","pubTimestamp":1732546505,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Nuvectis Pharma, Inc.  lately. While the stock has lost 52.8% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.Understanding Hammer Chart and the Technique to Trade It. If this is not enough, you should note that NVCT currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-nvct-forms-hammer-145505916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PEGI","BK4139","LU0823414478.USD","IE00BFMHRM44.USD","LU2211815571.USD","LU2249611893.SGD","LU2048586759.USD","GTLS","LU2264538146.SGD","NVCT","BK4161","LU1064131342.USD","LU1988902786.USD"],"gpt_icon":0},{"id":"2483637548","title":"Nuvectis Pharma reports data from Phase 1b study of NXP800","url":"https://stock-news.laohu8.com/highlight/detail?id=2483637548","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483637548?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:45","pubTimestamp":1731674718,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration and NXP800 was granted Orphan Drug Designation by the FDA for the treatment of ARID1a deficient ovarian, fallopian tube and primary peritoneal cancers. The Phase 1b interim data reported earlier this year included four patients evaluable for safety, of which three experienced Grade 4 thrombocytopenia. Subsequently, in the eight patients treated with NXP800 using the intermittent dosing schedule, the highest grade of thrombocytopenia observed was Grade 2. Other than thrombocytopenia, the most common treatment emergent adverse events included","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xBumZ4QcpNk7wPW_.v5BJw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-reports-data-phase-124518523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2483361343","title":"Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483361343","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483361343?lang=en_us&edition=fundamental","pubTime":"2024-11-15 03:23","pubTimestamp":1731612218,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma, Inc.  stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer.Three dosing regimens have been evaluated in twelve patients (four patients were treated on a once-per-day dosing schedule, two with 75 mg/day and two with 50 mg/day.Subsequently, eight additional patients were treated with 50 mg/day on an intermittent dosing schedule of five days on / two days off, a dosing schedule implemented to mitigate thrombocytopenia).All patients enrolled into the study failed at least two prior lines of systemic chemotherapy, including at least one prior platinum-based chemotherapy regimen, and most had also failed treatment with bevacizumab.In eleven efficacy-evaluable patients, antitumor activity was observed with best responses, including one with an unconfirmed partial response and six patients with stable disease, including tumor shrinkage.The Phase 1b interim data reporte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zIBYxgb6TBGHb2jvmfN1yA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7f676725e7a6cb210e2e171e280059c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zIBYxgb6TBGHb2jvmfN1yA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7f676725e7a6cb210e2e171e280059c7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-ceo-says-increased-192338282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2483383490","title":"Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483383490?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:55","pubTimestamp":1731599750,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target of $21.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-nuvectis-pharma-promising-clinical-and-preclinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-nuvectis-pharma-promising-clinical-and-preclinical-developments-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"gpt_icon":0},{"id":"2483388816","title":"Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483388816","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483388816?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:31","pubTimestamp":1731598260,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only minimized the severity of a condition in patients that causes abnormally low amount of platelets.Shares fell 44% to $5.99 in recent trading. The stock is down almost 39% this year.Earlier this year, the interim data reported for the Phase 1b study in patients with platinum resistant ARID1a-mutated ovarian cancer included four patients, of which three experienced Grade 4 thrombocytopenia. In the eight patients treated with NXP800 using an intermittent dosing schedule, the highest grade of thrombocytopenia observed was Grade 2.The NXP800 development program in this type of ovarian cancer was granted fast-track designation by the U.S. Food and Drug Administration.Other than thrombocytopenia, the most common treatment emergent adverse events included nausea, fatigue, vomiting, diarrhea and constipa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2483028158","title":"US Stocks Edge Lower; Cisco Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2483028158","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483028158?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:55","pubTimestamp":1731596122,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/24/11/41975433/us-stocks-edge-lower-cisco-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GXAI","VISL","CSCO","SOWG","UAVS","ELAB","NVCT"],"gpt_icon":0},{"id":"2483245802","title":"Nuvectis Pharma Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2483245802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483245802?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:51","pubTimestamp":1731595898,"startTime":"0","endTime":"0","summary":"09:46 EST Nuvectis Pharma (NVCT) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-inc-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2483809007","title":"Nuvectis Pharma Says Trial of Cancer Drug NXP800 Demonstrates Tumor Shrinkage","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809007?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:32","pubTimestamp":1731594742,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Thursday its phase 1b trial to evaluate NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer demonstrated antitumor activity, including tumor shrinkage.\"The antitumor activity observed despite patients' advanced disease and extensive pre-treatment, while controlling for thrombocytopenia, is promising,\" said Ron Bentsur, CEO of Nuvectis.The company expects to report additional clinical data from the trial in Q2 of next year, Bentsur said.NXP800 was granted orphan drug designation by the US Food and Drug Administration in August.Nuvectis Pharma shares were 54% lower in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2483809120","title":"Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809120","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809120?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:25","pubTimestamp":1731594302,"startTime":"0","endTime":"0","summary":"US stocks were treading water ahead of the opening bell Thursday as investors parse initial jobless claims figures and the latest producer price index reading.Dow Jones Industrial Average futures were","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BTC.USD.HKCC","CLDI","XBTmain","BK4211","HROW","QUBT","BK4591","BK4023","BTCmain","BK4007","BK4539","BK4085","BK4595","DBGI","BTCT","BTCS","NVCT","BK4204","BK4557","BK4094","FUNC","BWMN","BK4122","BK4139","GXAI","BK4129","GXAI.AU"],"gpt_icon":1},{"id":"2483871621","title":"BRIEF-Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483871621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483871621?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:25","pubTimestamp":1731587103,"startTime":"0","endTime":"0","summary":"Nov 14  - Nuvectis Pharma Inc   :   * NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER   * NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA EXPECTED IN Q2 2025Source text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2483766468","title":"Nuvectis Pharma Inc - Additional Phase 1B Clinical Data Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483766468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483766468?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA5N7DMN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2483506876","title":"Nuvectis Pharma Reports Encouraging Nxp800 Interim Data Supporting Ongoing Enrollment in Phase 1B Study in Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483506876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483506876?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA5N7DMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2483876733","title":"Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876733?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"NXP800 demonstrated single agent activity   New dosing schedule successfully minimized thrombocytopenia    Fort Lee, NJ, Nov.  14, 2024  (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a cli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981017/0/en/Nuvectis-Pharma-Reports-Encouraging-NXP800-Interim-Data-Supporting-Ongoing-Enrollment-in-Phase-1b-Study-in-Patients-with-Platinum-Resistant-ARID1a-Mutated-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT","BK4139"],"gpt_icon":1},{"id":"2483801808","title":"Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2483801808","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483801808?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:50","pubTimestamp":1731505809,"startTime":"0","endTime":"0","summary":"While \"the trend is your friend\" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Investors looking to make a profit from stocks that are currently on the move may find our \"Recent Price Strength\" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.In addition to NVCT, there are several other stocks that currently pass through our \"Recent Price Strength\" screen. You","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-nvct-great-choice-135009141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4142","NVCT","BK4139","CHH","BK4211","ISBC"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVCT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"NVCT","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.27},{"market":"US","date":"2025-02-25","symbol":"NVCT","fiscalQuarterEnding":"2024/12","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2024-11-05","symbol":"NVCT","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730782800000,"reportTimeType":"pre","actualEps":-0.24},{"market":"US","date":"2024-08-06","symbol":"NVCT","fiscalQuarterEnding":"2024/06","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-05-07","symbol":"NVCT","fiscalQuarterEnding":"2024/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"pre","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVCT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NVCT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NVCT","date":"2025-05-09","current":-10.697367,"percent":0.249364,"low":-4822.163542,"twenty":-11.237045,"median":-7.846568,"eighty":-5.884079,"high":-4.507629,"avg":-157.844899,"sd":726.849078,"marketCap":215669620},"quantilePoints":[{"date":"2022-02-04","current":-1722.20125,"twenty":-2416.901458,"median":-2416.901458,"eighty":-2000.081333,"marketCap":41332830},{"date":"2022-02-11","current":-3677.562083,"twenty":-3582.178633,"median":-3306.626438,"eighty":-2416.901458,"marketCap":88261490},{"date":"2022-02-18","current":-3105.261333,"twenty":-3521.769108,"median":-3195.345708,"eighty":-2596.861958,"marketCap":74526272},{"date":"2022-02-25","current":-3359.617208,"twenty":-3425.325841,"median":-3227.140208,"eighty":-2883.759766,"marketCap":80630813},{"date":"2022-03-04","current":-3990.207833,"twenty":-3634.109608,"median":-3354.318146,"eighty":-2982.322667,"marketCap":95764988},{"date":"2022-03-11","current":-4382.339833,"twenty":-4096.189467,"median":-3439.103458,"eighty":-3123.278208,"marketCap":105176156},{"date":"2022-03-18","current":-4149.180292,"twenty":-4143.881209,"median":-3592.776792,"eighty":-3195.345708,"marketCap":99580327},{"date":"2022-03-25","current":-7.409669,"twenty":-4111.026892,"median":-3439.103458,"eighty":-2883.759766,"marketCap":95510632},{"date":"2022-04-01","current":-6.926215,"twenty":-4060.1557,"median":-3354.318146,"eighty":-350.415344,"marketCap":89278913},{"date":"2022-04-08","current":-9.323751,"twenty":-4037.899584,"median":-3227.140208,"eighty":-8.266073,"marketCap":120183153},{"date":"2022-04-14","current":-9.965067,"twenty":-4016.70325,"median":-3195.345708,"eighty":-8.337111,"marketCap":128449719},{"date":"2022-04-22","current":-9.550678,"twenty":-3990.207833,"median":-3028.424667,"eighty":-9.234954,"marketCap":123108245},{"date":"2022-04-29","current":-9.373083,"twenty":-3905.422542,"median":-2416.901458,"eighty":-9.234954,"marketCap":120819043},{"date":"2022-05-06","current":-17.956854,"twenty":-3677.562083,"median":-870.079052,"eighty":-9.234954,"marketCap":231463850},{"date":"2022-05-13","current":-15.163214,"twenty":-3640.4685,"median":-14.858803,"eighty":-9.323751,"marketCap":239730416},{"date":"2022-05-20","current":-12.468425,"twenty":-3608.674042,"median":-15.011008,"eighty":-9.373083,"marketCap":197125807},{"date":"2022-05-27","current":-12.597132,"twenty":-3576.879542,"median":-14.366844,"eighty":-9.373083,"marketCap":199160654},{"date":"2022-06-03","current":-9.773637,"twenty":-3517.529842,"median":-13.793232,"eighty":-9.396762,"marketCap":154521197},{"date":"2022-06-10","current":-9.652975,"twenty":-3451.82125,"median":-12.774103,"eighty":-9.410576,"marketCap":152613528},{"date":"2022-06-17","current":-8.824428,"twenty":-3383.992992,"median":-12.70975,"eighty":-9.363217,"marketCap":139514200},{"date":"2022-06-24","current":-9.242723,"twenty":-3363.856475,"median":-12.468425,"eighty":-9.239615,"marketCap":146127453},{"date":"2022-07-01","current":-9.64493,"twenty":-3353.258333,"median":-11.474627,"eighty":-9.239615,"marketCap":152486350},{"date":"2022-07-08","current":-10.224109,"twenty":-3315.104967,"median":-10.465433,"eighty":-9.275134,"marketCap":161643161},{"date":"2022-07-15","current":-9.086265,"twenty":-3249.396358,"median":-10.409124,"eighty":-9.258683,"marketCap":143653842},{"date":"2022-07-22","current":-9.586449,"twenty":-3214.422408,"median":-10.216065,"eighty":-9.238062,"marketCap":151561766},{"date":"2022-07-29","current":-7.078848,"twenty":-3195.345708,"median":-9.9848,"eighty":-9.113213,"marketCap":111916587},{"date":"2022-08-05","current":-8.052111,"twenty":-3195.345708,"median":-9.910387,"eighty":-8.975658,"marketCap":108228426},{"date":"2022-08-12","current":-9.488582,"twenty":-3159.311958,"median":-9.805813,"eighty":-8.932791,"marketCap":127536026},{"date":"2022-08-19","current":-9.793611,"twenty":-3043.792,"median":-9.810606,"eighty":-8.975658,"marketCap":131635922},{"date":"2022-08-26","current":-9.510369,"twenty":-2917.673883,"median":-9.781681,"eighty":-9.015878,"marketCap":127828876},{"date":"2022-09-02","current":-9.031038,"twenty":-2686.842208,"median":-9.757814,"eighty":-8.975658,"marketCap":121386184},{"date":"2022-09-09","current":-9.150871,"twenty":-2416.901458,"median":-9.745482,"eighty":-8.964396,"marketCap":122996857},{"date":"2022-09-16","current":-8.932993,"twenty":-2277.961416,"median":-9.701239,"eighty":-8.937021,"marketCap":120068360},{"date":"2022-09-23","current":-8.573495,"twenty":-1381.352371,"median":-9.632337,"eighty":-8.826532,"marketCap":115236341},{"date":"2022-09-30","current":-7.723771,"twenty":-17.65393,"median":-9.586518,"eighty":-8.651931,"marketCap":103815204},{"date":"2022-10-07","current":-7.63662,"twenty":-16.210562,"median":-9.563205,"eighty":-8.405729,"marketCap":102643805},{"date":"2022-10-14","current":-7.603938,"twenty":-15.261352,"median":-9.524268,"eighty":-8.26218,"marketCap":102204531},{"date":"2022-10-21","current":-7.680195,"twenty":-15.169649,"median":-9.483135,"eighty":-8.073594,"marketCap":103229505},{"date":"2022-10-28","current":-7.810268,"twenty":-15.102332,"median":-9.471747,"eighty":-7.885,"marketCap":104977817},{"date":"2022-11-04","current":-7.576703,"twenty":-14.768455,"median":-9.451943,"eighty":-7.747738,"marketCap":101838469},{"date":"2022-11-11","current":-6.796511,"twenty":-14.399021,"median":-9.402682,"eighty":-7.680195,"marketCap":99568884},{"date":"2022-11-18","current":-7.224291,"twenty":-14.29948,"median":-9.348417,"eighty":-7.640977,"marketCap":105835867},{"date":"2022-11-25","current":-7.26627,"twenty":-14.030026,"median":-9.293004,"eighty":-7.625726,"marketCap":106450851},{"date":"2022-12-02","current":-7.506147,"twenty":-13.793232,"median":-9.25981,"eighty":-7.576703,"marketCap":109965047},{"date":"2022-12-09","current":-7.506147,"twenty":-12.999339,"median":-9.210288,"eighty":-7.516141,"marketCap":109965047},{"date":"2022-12-16","current":-7.406198,"twenty":-12.782147,"median":-9.150762,"eighty":-7.496152,"marketCap":108500799},{"date":"2022-12-23","current":-7.738527,"twenty":-12.766059,"median":-9.1187,"eighty":-7.454973,"marketCap":113369424},{"date":"2022-12-30","current":-7.496152,"twenty":-12.766059,"median":-9.099176,"eighty":-7.44634,"marketCap":109818622},{"date":"2023-01-06","current":-7.594801,"twenty":-12.732274,"median":-9.091333,"eighty":-7.450405,"marketCap":111263835},{"date":"2023-01-13","current":-7.406198,"twenty":-12.642179,"median":-9.041932,"eighty":-7.450257,"marketCap":108500799},{"date":"2023-01-20","current":-7.496152,"twenty":-12.545649,"median":-9.025531,"eighty":-7.451274,"marketCap":109818622},{"date":"2023-01-27","current":-7.975905,"twenty":-12.317195,"median":-8.981288,"eighty":-7.451274,"marketCap":116847014},{"date":"2023-02-03","current":-10.369677,"twenty":-11.855901,"median":-9.025531,"eighty":-7.452843,"marketCap":151915761},{"date":"2023-02-10","current":-14.362627,"twenty":-11.979785,"median":-9.058273,"eighty":-7.455453,"marketCap":210412480},{"date":"2023-02-17","current":-9.964884,"twenty":-11.831926,"median":-9.096402,"eighty":-7.46125,"marketCap":145985555},{"date":"2023-02-24","current":-10.434643,"twenty":-11.751993,"median":-9.101951,"eighty":-7.472325,"marketCap":152867522},{"date":"2023-03-03","current":-11.973853,"twenty":-11.789947,"median":-9.134127,"eighty":-7.486157,"marketCap":175416946},{"date":"2023-03-10","current":-8.326972,"twenty":-11.789947,"median":-9.107295,"eighty":-7.488136,"marketCap":158920261},{"date":"2023-03-17","current":-9.237161,"twenty":-11.658015,"median":-9.099176,"eighty":-7.496072,"marketCap":176291215},{"date":"2023-03-24","current":-9.086429,"twenty":-11.512116,"median":-9.107295,"eighty":-7.496152,"marketCap":173414497},{"date":"2023-03-31","current":-10.133823,"twenty":-11.492386,"median":-9.134127,"eighty":-7.496152,"marketCap":193404003},{"date":"2023-04-06","current":-9.75506,"twenty":-11.456868,"median":-9.150762,"eighty":-7.496152,"marketCap":186175325},{"date":"2023-04-14","current":-11.478815,"twenty":-11.451785,"median":-9.210288,"eighty":-7.496152,"marketCap":219073184},{"date":"2023-04-21","current":-10.705831,"twenty":-11.440849,"median":-9.236058,"eighty":-7.496152,"marketCap":204320781},{"date":"2023-04-28","current":-11.463355,"twenty":-11.463355,"median":-9.251266,"eighty":-7.496152,"marketCap":218778136},{"date":"2023-05-01","current":-12.211645,"twenty":-11.469477,"median":-9.25981,"eighty":-7.496152,"marketCap":233059240},{"date":"2023-05-12","current":-11.89369,"twenty":-11.658015,"median":-9.26808,"eighty":-7.496152,"marketCap":240145501},{"date":"2023-05-19","current":-13.141553,"twenty":-11.893853,"median":-9.303385,"eighty":-7.4981,"marketCap":265341095},{"date":"2023-05-26","current":-13.572736,"twenty":-12.376667,"median":-9.373083,"eighty":-7.505944,"marketCap":274047116},{"date":"2023-06-02","current":-13.905712,"twenty":-12.463106,"median":-9.391925,"eighty":-7.506147,"marketCap":280770234},{"date":"2023-06-09","current":-13.897784,"twenty":-12.70975,"median":-9.412549,"eighty":-7.506147,"marketCap":280610160},{"date":"2023-06-16","current":-14.42896,"twenty":-12.999339,"median":-9.452014,"eighty":-7.506147,"marketCap":291335135},{"date":"2023-06-23","current":-14.056344,"twenty":-13.239822,"median":-9.471747,"eighty":-7.514142,"marketCap":283811645},{"date":"2023-06-30","current":-12.954352,"twenty":-13.244502,"median":-9.481102,"eighty":-7.534132,"marketCap":261561324},{"date":"2023-07-07","current":-12.034704,"twenty":-13.213305,"median":-9.499475,"eighty":-7.55812,"marketCap":242992711},{"date":"2023-07-14","current":-12.082272,"twenty":-13.164951,"median":-9.548401,"eighty":-7.576348,"marketCap":243953157},{"date":"2023-07-21","current":-11.321184,"twenty":-13.104727,"median":-9.564908,"eighty":-7.580464,"marketCap":228586029},{"date":"2023-07-28","current":-11.154696,"twenty":-13.046317,"median":-9.586518,"eighty":-7.586105,"marketCap":225224469},{"date":"2023-08-04","current":-11.4956,"twenty":-13.024672,"median":-9.61481,"eighty":-7.589583,"marketCap":232107662},{"date":"2023-08-11","current":-11.568146,"twenty":-12.981344,"median":-9.64493,"eighty":-7.595321,"marketCap":258316695},{"date":"2023-08-18","current":-11.190253,"twenty":-12.938496,"median":-9.709283,"eighty":-7.5961,"marketCap":249878349},{"date":"2023-08-25","current":-11.167117,"twenty":-12.914712,"median":-9.749504,"eighty":-7.599235,"marketCap":249361716},{"date":"2023-09-01","current":-11.036011,"twenty":-12.870315,"median":-9.760327,"eighty":-7.612653,"marketCap":246434127},{"date":"2023-09-08","current":-11.151692,"twenty":-12.799405,"median":-9.777659,"eighty":-7.625726,"marketCap":249017293},{"date":"2023-09-15","current":-10.81236,"twenty":-12.778929,"median":-9.805813,"eighty":-7.625726,"marketCap":241440004},{"date":"2023-09-22","current":-10.550149,"twenty":-12.766059,"median":-9.8581,"eighty":-7.627797,"marketCap":235584825},{"date":"2023-09-29","current":-10.642694,"twenty":-12.754797,"median":-9.91491,"eighty":-7.636188,"marketCap":237651359},{"date":"2023-10-06","current":-8.38305,"twenty":-12.687226,"median":-9.900583,"eighty":-7.63662,"marketCap":187193498},{"date":"2023-10-13","current":-7.380477,"twenty":-12.582954,"median":-9.815398,"eighty":-7.63662,"marketCap":164806051},{"date":"2023-10-20","current":-6.994872,"twenty":-12.517778,"median":-9.787646,"eighty":-7.625726,"marketCap":156195494},{"date":"2023-10-27","current":-6.856054,"twenty":-12.500855,"median":-9.777659,"eighty":-7.617011,"marketCap":153095694},{"date":"2023-11-03","current":-7.295644,"twenty":-12.474627,"median":-9.75506,"eighty":-7.591323,"marketCap":162911728},{"date":"2023-11-10","current":-6.384789,"twenty":-12.465234,"median":-9.745482,"eighty":-7.564117,"marketCap":142597868},{"date":"2023-11-17","current":-6.361515,"twenty":-12.460749,"median":-9.701239,"eighty":-7.506147,"marketCap":142078070},{"date":"2023-11-24","current":-6.361515,"twenty":-12.450927,"median":-9.64493,"eighty":-7.496152,"marketCap":142078070},{"date":"2023-12-01","current":-6.594253,"twenty":-12.430299,"median":-9.61481,"eighty":-7.496152,"marketCap":147276049},{"date":"2023-12-08","current":-6.547705,"twenty":-12.335412,"median":-9.586518,"eighty":-7.486157,"marketCap":146236453},{"date":"2023-12-15","current":-6.625285,"twenty":-12.194779,"median":-9.564908,"eighty":-7.452843,"marketCap":147969112},{"date":"2023-12-22","current":-6.260661,"twenty":-12.140939,"median":-9.548401,"eighty":-7.432254,"marketCap":139825613},{"date":"2023-12-29","current":-6.648559,"twenty":-12.098128,"median":-9.517319,"eighty":-7.416193,"marketCap":148488910},{"date":"2024-01-05","current":-6.4934,"twenty":-12.093462,"median":-9.488582,"eighty":-7.408281,"marketCap":145023591},{"date":"2024-01-12","current":-7.54848,"twenty":-12.085504,"median":-9.474718,"eighty":-7.408281,"marketCap":168587759},{"date":"2024-01-19","current":-6.439094,"twenty":-12.082272,"median":-9.46188,"eighty":-7.391646,"marketCap":143810730},{"date":"2024-01-26","current":-5.996891,"twenty":-12.063245,"median":-9.451871,"eighty":-7.358883,"marketCap":133934571},{"date":"2024-02-02","current":-5.539173,"twenty":-12.010364,"median":-9.403927,"eighty":-7.324002,"marketCap":123711881},{"date":"2024-02-09","current":-5.345224,"twenty":-11.96331,"median":-9.373083,"eighty":-7.303747,"marketCap":119380232},{"date":"2024-02-16","current":-6.105503,"twenty":-11.93164,"median":-9.313568,"eighty":-7.27802,"marketCap":136360294},{"date":"2024-02-23","current":-5.787427,"twenty":-11.905064,"median":-9.279216,"eighty":-7.226222,"marketCap":129256391},{"date":"2024-03-01","current":-7.657092,"twenty":-11.893853,"median":-9.25981,"eighty":-7.201903,"marketCap":171013482},{"date":"2024-03-08","current":-8.110119,"twenty":-11.888595,"median":-9.239942,"eighty":-7.226222,"marketCap":180531251},{"date":"2024-03-15","current":-7.303897,"twenty":-11.863459,"median":-9.185622,"eighty":-7.234415,"marketCap":162584739},{"date":"2024-03-22","current":-7.224073,"twenty":-11.84433,"median":-9.144455,"eighty":-7.224117,"marketCap":160807857},{"date":"2024-03-28","current":-6.657322,"twenty":-11.84392,"median":-9.1187,"eighty":-7.196306,"marketCap":148191992},{"date":"2024-04-05","current":-6.154431,"twenty":-11.813935,"median":-9.096402,"eighty":-7.141402,"marketCap":136997633},{"date":"2024-04-12","current":-5.922941,"twenty":-11.807221,"median":-9.086347,"eighty":-7.106352,"marketCap":131844674},{"date":"2024-04-19","current":-5.364173,"twenty":-11.73344,"median":-9.082564,"eighty":-7.087417,"marketCap":119406497},{"date":"2024-04-26","current":-5.196543,"twenty":-11.725512,"median":-9.036485,"eighty":-7.056377,"marketCap":115675044},{"date":"2024-05-03","current":-5.5789,"twenty":-11.693997,"median":-9.020144,"eighty":-6.994872,"marketCap":124186324},{"date":"2024-05-10","current":-5.232404,"twenty":-11.670016,"median":-8.943064,"eighty":-6.926009,"marketCap":117111662},{"date":"2024-05-17","current":-5.355423,"twenty":-11.568146,"median":-8.86763,"eighty":-6.867017,"marketCap":119865071},{"date":"2024-05-24","current":-5.478442,"twenty":-11.551096,"median":-8.824241,"eighty":-6.807818,"marketCap":122618480},{"date":"2024-05-31","current":-5.248806,"twenty":-11.540057,"median":-8.78056,"eighty":-6.750346,"marketCap":117478784},{"date":"2024-06-07","current":-5.355423,"twenty":-11.535651,"median":-8.71467,"eighty":-6.643904,"marketCap":119865071},{"date":"2024-06-14","current":-5.601461,"twenty":-11.522593,"median":-8.700328,"eighty":-6.585481,"marketCap":125371889},{"date":"2024-06-21","current":-5.601461,"twenty":-11.514132,"median":-8.595282,"eighty":-6.550808,"marketCap":125371889},{"date":"2024-06-28","current":-5.14219,"twenty":-11.514103,"median":-8.591276,"eighty":-6.544445,"marketCap":115092496},{"date":"2024-07-05","current":-5.084781,"twenty":-11.509505,"median":-8.549205,"eighty":-6.524432,"marketCap":113807572},{"date":"2024-07-12","current":-5.248806,"twenty":-11.505115,"median":-8.477607,"eighty":-6.501158,"marketCap":117478784},{"date":"2024-07-15","current":-5.396429,"twenty":-11.504671,"median":-8.471907,"eighty":-6.499606,"marketCap":120782874},{"date":"2024-08-02","current":-5.068379,"twenty":-11.504226,"median":-8.439046,"eighty":-6.4934,"marketCap":113440450},{"date":"2024-08-09","current":-6.04608,"twenty":-11.4956,"median":-8.380128,"eighty":-6.446852,"marketCap":127584385},{"date":"2024-08-16","current":-5.568758,"twenty":-11.4956,"median":-8.33936,"eighty":-6.431336,"marketCap":117511934},{"date":"2024-08-23","current":-6.364295,"twenty":-11.487672,"median":-8.317646,"eighty":-6.400304,"marketCap":134299353},{"date":"2024-08-30","current":-6.001884,"twenty":-11.478815,"median":-8.282792,"eighty":-6.361515,"marketCap":126651751},{"date":"2024-09-06","current":-5.445008,"twenty":-11.472569,"median":-8.234715,"eighty":-6.361515,"marketCap":114900558},{"date":"2024-09-13","current":-5.745544,"twenty":-11.464886,"median":-8.172852,"eighty":-6.350611,"marketCap":121242472},{"date":"2024-09-20","current":-5.966527,"twenty":-11.457439,"median":-8.106128,"eighty":-6.299451,"marketCap":125905644},{"date":"2024-09-27","current":-5.445008,"twenty":-11.447214,"median":-8.0288,"eighty":-6.249174,"marketCap":114900558},{"date":"2024-10-04","current":-5.445008,"twenty":-11.428314,"median":-7.993998,"eighty":-6.196292,"marketCap":114900558},{"date":"2024-10-11","current":-5.471526,"twenty":-11.41595,"median":-7.975905,"eighty":-6.137667,"marketCap":115460138},{"date":"2024-10-18","current":-5.975366,"twenty":-11.389225,"median":-7.92057,"eighty":-6.076134,"marketCap":126092170},{"date":"2024-10-25","current":-7.734386,"twenty":-11.342169,"median":-7.870838,"eighty":-6.088277,"marketCap":163211020},{"date":"2024-10-31","current":-6.974207,"twenty":-11.32549,"median":-7.854682,"eighty":-6.099297,"marketCap":147169708},{"date":"2024-11-08","current":-8.029494,"twenty":-11.299815,"median":-7.828418,"eighty":-6.086567,"marketCap":155563417},{"date":"2024-11-15","current":-5.516667,"twenty":-11.283906,"median":-7.854682,"eighty":-6.086567,"marketCap":106879902},{"date":"2024-11-22","current":-4.886589,"twenty":-11.259662,"median":-7.803133,"eighty":-6.007187,"marketCap":94672767},{"date":"2024-11-29","current":-5.026205,"twenty":-11.229851,"median":-7.772793,"eighty":-5.982437,"marketCap":97377703},{"date":"2024-12-06","current":-4.746972,"twenty":-11.207233,"median":-7.743226,"eighty":-5.930799,"marketCap":91967831},{"date":"2024-12-13","current":-4.6273,"twenty":-11.199507,"median":-7.732114,"eighty":-5.891293,"marketCap":89649314},{"date":"2024-12-20","current":-4.677163,"twenty":-11.187168,"median":-7.695034,"eighty":-5.858687,"marketCap":90615363},{"date":"2024-12-27","current":-5.00626,"twenty":-11.179456,"median":-7.680195,"eighty":-5.833974,"marketCap":96991284},{"date":"2025-01-03","current":-5.375247,"twenty":-11.167117,"median":-7.680195,"eighty":-5.765486,"marketCap":104140044},{"date":"2025-01-10","current":-6.153113,"twenty":-11.15718,"median":-7.674115,"eighty":-5.765219,"marketCap":119210403},{"date":"2025-01-17","current":-5.445056,"twenty":-11.152293,"median":-7.657092,"eighty":-5.745544,"marketCap":105492512},{"date":"2025-01-24","current":-6.402428,"twenty":-11.143981,"median":-7.63662,"eighty":-5.743678,"marketCap":124040646},{"date":"2025-01-31","current":-6.721552,"twenty":-11.137297,"median":-7.62606,"eighty":-5.745544,"marketCap":130223358},{"date":"2025-02-07","current":-8.933023,"twenty":-11.094623,"median":-7.625726,"eighty":-5.756709,"marketCap":173068391},{"date":"2025-02-14","current":-8.575209,"twenty":-11.04835,"median":-7.63608,"eighty":-5.764953,"marketCap":166136094},{"date":"2025-02-21","current":-9.278499,"twenty":-11.027345,"median":-7.63662,"eighty":-5.774262,"marketCap":179761644},{"date":"2025-02-28","current":-8.442054,"twenty":-11.010673,"median":-7.657749,"eighty":-5.790095,"marketCap":160399020},{"date":"2025-03-07","current":-7.571459,"twenty":-11.00084,"median":-7.658407,"eighty":-5.794098,"marketCap":143857718},{"date":"2025-03-14","current":-10.279948,"twenty":-10.991897,"median":-7.680195,"eighty":-5.810034,"marketCap":195319016},{"date":"2025-03-21","current":-11.51108,"twenty":-11.024301,"median":-7.680195,"eighty":-5.833952,"marketCap":218710515},{"date":"2025-03-28","current":-11.880419,"twenty":-11.05452,"median":-7.709402,"eighty":-5.833974,"marketCap":225727965},{"date":"2025-04-04","current":-11.14174,"twenty":-11.147711,"median":-7.734386,"eighty":-5.837495,"marketCap":211693065},{"date":"2025-04-11","current":-10.495396,"twenty":-11.14058,"median":-7.744393,"eighty":-5.846312,"marketCap":199412528},{"date":"2025-04-17","current":-10.710844,"twenty":-11.149702,"median":-7.758662,"eighty":-5.855152,"marketCap":203506041},{"date":"2025-04-25","current":-13.493202,"twenty":-11.164633,"median":-7.795998,"eighty":-5.871062,"marketCap":256370829},{"date":"2025-05-02","current":-11.843485,"twenty":-11.207752,"median":-7.810247,"eighty":-5.879113,"marketCap":225026220},{"date":"2025-05-09","current":-10.697367,"twenty":-11.237045,"median":-7.846568,"eighty":-5.884079,"marketCap":215669620}],"updateTime":1746921907030}}}